Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(03): 60-63
DOI: 10.1055/s-0041-1733182
Letter to the Editor

Letrozole as first Line Adjuvant Hormonal Therapy in Breast Cancer - a Preliminary Study

G Sudarshan
Indo-American Cancer Institute and Research Center, Rd No. 14, Banjara Hills, Hyderabad-500034, India
,
M.G Rama Rao
Indo-American Cancer Institute and Research Center, Rd No. 14, Banjara Hills, Hyderabad-500034, India
,
K.V.V.N Raju
Indo-American Cancer Institute and Research Center, Rd No. 14, Banjara Hills, Hyderabad-500034, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2006. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Early breast cancer Trialists' Collaborative Group.Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 1998;351:1451-67.
  • 2 National Institute of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3,2000.J Natl Cancer Inst Monogr, 2001;30:5-15.
  • 3 Mouridsen H, Genshanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol, 2001;19:2596-606.
  • 4 Fisher B, Constantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 1998;90:1371-88.
  • 5 Mouridsen H, Gershanovich M: The role of aromatase inhibitors in the treatment of metastatic breast cancer. Semin Oncol, 2003;30:33-45.
  • 6 van Laneghem AA, Poortman J, Nabuurs M, et al: Endogenous concentration and sub cellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res, 1985;45:2900-6.
  • 7 Buzdar AU, Robertson JFR, Eirmann W, et al: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer, 2002;95:2006-16.
  • 8 Janicke F: Are all aromatase inhibitors the same? A review of the current evidence. The Breast, 2004;13:S10- S18.
  • 9 Lonning P, Pfister C, Martoni, et al: Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol, 2003;30:23-32.
  • 10 Buzdar A, Douma J, Davidson, et a: Phase II, multicenter, double blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol, 2001;19:3357-66.
  • 11 Gershanovich M, Chaudri HA, Campos d, etal: Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR / BC3). Ann Oncol, 1998;9:639-45.
  • 12 Goss PE, Ingle JN, Martino s, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med, 2003;349:1793-802.
  • 13 Winer EP, Hudis C, Burstein HJ and Wolff AC et al: American Society of Clinical Oncology Technology assessment on the use of aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor breast cancer status. Report 2004. J Clin Oncol, 2005;23.